Mirati Therape…
ProfileJobs

Mirati Therapeutics

Suggest Edit
    • Healthbiotechdrug developmentoncologypharma

    Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

    Market capitalization(2018-06-15)
    $1.6 B
    Type
    Public
    HQ
    San Diego, US
    Founded
    2013
    Size (employees)
    38 (est)
    Website
    mirati.com
    Mirati Therapeutics was founded in 2013 and is headquartered in San Diego, US
    Report incorrect company information

    Mirati Therapeutics Office Locations

    Mirati Therapeutics has an office in San Diego
    San Diego, US (HQ)
    200 9393 Towne Centre Dr
    Show all (1)
    Report incorrect company information

    Mirati Therapeutics Financials and Metrics

    Mirati Therapeutics Financials

    USD

    Revenue (Q1, 2018)

    		9.5 m

    Net income (Q1, 2018)

    		(14.7 m)

    EBIT (Q1, 2018)

    		(15.3 m)

    Market capitalization (15-Jun-2018)

    		1.6 b

    Closing share price (15-Jun-2018)

    		49

    Cash (31-Mar-2018)

    		20.6 m
    Mirati Therapeutics's current market capitalization is $1.6 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    General and administrative expense

    		15.3 m13.5 m

    R&D expense

    		68.5 m58.1 m

    Operating expense total

    		83.8 m71.5 m

    EBIT

    		(32 m)(39.1 m)(64.7 m)(83.8 m)(71.5 m)
    Quarterly
    USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		9.5 m

    General and administrative expense

    		2.4 m2.9 m3.5 m3.8 m4.2 m4.2 m4.1 m3.8 m3.5 m3.7 m3.7 m5.2 m

    R&D expense

    		5.2 m7.2 m7 m8.2 m11.3 m14.6 m18 m18.4 m16.1 m14.4 m15 m19.7 m

    Operating expense total

    		8 m10.1 m10.5 m12 m15.5 m18.7 m22.1 m22.2 m19.6 m18.1 m18.6 m24.8 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		14.2 m6.6 m49.5 m22.4 m107.7 m

    Accounts Receivable

    Inventories

    Current Assets

    		64.2 m32.7 m125.4 m59.6 m155.8 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Cash

    		7.6 m8.3 m8.5 m4.9 m14.3 m13.4 m109.9 m34.6 m24.5 m19.8 m29.8 m20 m20.6 m

    Current Assets

    		17 m56 m49.2 m40.3 m71.2 m60.9 m141 m109.9 m93 m75.5 m107.9 m92.3 m153.1 m

    PP&E

    		427 k275 k479 k524 k667 k693 k639 k601 k558 k537 k638 k618 k484 k

    Total Assets

    		18 m56.3 m49.7 m41.3 m72.2 m61.9 m143.7 m112.5 m96 m79.2 m110.8 m95 m154.5 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(43.7 m)(64.5 m)(83.1 m)(70.4 m)

    Depreciation and Amortization

    		171 k199 k212 k180 k184 k

    Inventories

    Accounts Payable

    		(1.3 m)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

    Net Income

    		(13.7 m)(11 m)(8.6 m)(11.9 m)(15.4 m)(18.7 m)(21.9 m)(22.1 m)(19.4 m)(17.8 m)(14.7 m)

    Depreciation and Amortization

    		105 k41 k

    Cash From Operating Activities

    		(7.9 m)

    Purchases of PP&E

    		(199 k)
    show all
    USDY, 2018

    Financial Leverage

    		1.1 x
    Show all financial metrics

    Mirati Therapeutics Operating Metrics

    FY, 2016

    Patents Issued

    		32

    Patents Pending

    		1
    Show all operating metrics
    Report incorrect company information

    Competitors

    AVEO Pharmaceuticals
    Health - Public
    Nektar Therapeutics
    Health - Public
    Clovis Oncology
    Health - Public
    Infinity Pharmaceuticals
    Health - Public
    Compare competitors

    Mirati Therapeutics Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Mirati Therapeutics News and Updates

    May 28, 2018

    Histone Deacetylase 1 Market By top manufactures Mirati Therapeutics Inc., Oncolys BioPharma Inc.

    Latest research study from HTF MI with title Global and United States Histone Deacetylase 1 by Manufacturers, Regions, Type and Application, Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
    Report incorrect company information
    Download PDF